Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 26, No 2 (January 10), 2008: pp. 242-245
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.4008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Berthold, D. R.
Right arrow Articles by Tannock, I. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthold, D. R.
Right arrow Articles by Tannock, I. F.
Related Articles
Right arrowRelated Correspondence

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Dominik R. Berthold, Gregory R. Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, Ian F. Tannock

From the Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada; Erasmus University Medical Center, Rotterdam, the Netherlands; and Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Corresponding author: Ian F. Tannock, MD, PhD, FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada; e-mail: ian.tannock{at}uhn.on.ca

Purpose: The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival.

Methods: Investigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003.

Results: By March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived ≥ 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%). Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.

Conclusion: The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?
    Chadi Nabhan
    JCO 2008 26: 2413-2414 [Full Text]


This article has been cited by other articles:


Home page
Ann OncolHome page
D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, and On behalf of the TAX 327 investigators
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Ann. Onc., May 16, 2008; (2008) mdn288v1.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Nabhan
Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?
J. Clin. Oncol., May 10, 2008; 26(14): 2413 - 2414.
[Full Text] [PDF]


Home page
JCOHome page
D. Berthold and I. Tannock
In Reply
J. Clin. Oncol., May 10, 2008; 26(14): 2414 - 2415.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. J. Armstrong, E. L. Garrett-Mayer, and M. Eisenberger
Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens
J Natl Cancer Inst, May 7, 2008; 100(9): 681 - 682.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. R. Berthold, G. R. Pond, M. Roessner, R. de Wit, M. Eisenberger, a. I. F. Tannock, and on behalf of the TAX-327 investigators
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Clin. Cancer Res., May 1, 2008; 14(9): 2763 - 2767.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
Long-Term Survival of Men Treated with Docetaxel and Prednisone for Prostate Cancer
Journal Watch Oncology and Hematology, February 5, 2008; 2008(205): 1 - 1.
[Full Text]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online